Table 3. Results from accelerated failure time model.
| Variables | Proportionate Change in Time to Decision | 95% CI | p-Value |
| Context | |||
| Natural log population (1,000s) | 1.14 | [0.89–1.46] | 0.285 |
| Region (compared to high-income OECD) | |||
| East Asia and Pacific | 2.47* | [1.02–5.95] | 0.044 |
| Europe and Central Asia | 3.33** | [1.67–6.67] | 0.001 |
| Latin America and Caribbean | 1.10 | [0.57–2.12] | 0.775 |
| Middle East and North Africa | 1.56 | [0.70–3.44] | 0.277 |
| Other high-income | 1.19 | [0.63–2.23] | 0.599 |
| South Asia | 2.58 | [0.80–8.27] | 0.112 |
| Sub-Saharan Africa | 1.40 | [0.56–3.37] | 0.448 |
| DTP3 coverage (%) | 0.99 | [0.98–1.00] | 0.059 |
| Democracy score | 0.97* | [0.94–1.00] | 0.041 |
| Costs and benefits | |||
| Natural log price per dose (US$) | 1.02* | [1.00–1.04] | 0.015 |
| Natural log GNI (US$) | 0.92 | [0.72–1.18] | 0.530 |
| Natural log cost per bed-day (Int$) | 1.00 | [0.81–1.22] | 0.972 |
| Incidence of Hib disease (per 100,000 child-years) | 1.02 | [0.97–1.07] | 0.434 |
| Availability of Hib in combination with DTP and/or HBV | 1.13 | [0.63–1.99] | 0.686 |
| Modifying factors | |||
| Local incidence/disease burden studies | 0.92 | [0.83–1.02] | 0.123 |
| Neighboring adopters (compared to none) | |||
| One neighboring country adopter | 0.67* | [0.48–0.94] | 0.021 |
| Two or more neighboring country adopters | 0.50** | [0.33–0.75] | 0.001 |
| WHO position paper (compared to none) | |||
| First WHO position | 0.94 | [0.57–1.53] | 0.787 |
| Second WHO position | 0.59 | [0.26–1.32] | 0.198 |
| GAVI eligibility | 0.37** | [0.18–0.75] | 0.007 |
| Cofinancing uncertainty | 2.26** | [1.23–4.15] | 0.009 |
| Constant | 28.69 | [0.82–994.53] | 0.064 |
*p<0.05, **p<0.01, Weibull distribution, Gaussian frailty. n = 1,383.